Terms: = Lung cancer AND ABL1, p150, 25, ENSG00000097007, P00519, v-abl, bcr/abl, JTK7, c-ABL, ABL, BCR-ABL AND Clinical Outcome
220 results:
1. clinical and Imaging Characteristics of SARS-CoV-2 Breakthrough Infection in Hospitalized Immunocompromised Patients.
Lee JE; Kim J; Hwang M; Kim YH; Chung MJ; Jeong WG; Jeong YJ
Korean J Radiol; 2024 May; 25(5):481-492. PubMed ID: 38627873
[TBL] [Abstract] [Full Text] [Related]
2. Circulating Immune Proteins: Improving the Diagnosis and clinical outcome in Advanced Non-Small Cell lung cancer.
Torres-Martínez S; Calabuig-Fariñas S; Gallach S; Mosqueda M; Munera-Maravilla E; Sirera R; Navarro L; Blasco A; Camps C; Jantus-Lewintre E
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139416
[TBL] [Abstract] [Full Text] [Related]
3. Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study.
Liu Y; Xiong L; Chen Y; Cai R; Xu X; Wang T; Guo Y; Ruan L; Fang Y; Zhang Q; Shen B; Ye J; Zhou G
Hum Vaccin Immunother; 2023 Dec; 19(3):2285902. PubMed ID: 38010104
[TBL] [Abstract] [Full Text] [Related]
4. clinical outcomes of
Hansen KH; Johansen JS; Urbanska EM; Meldgaard P; Hjorth-Hansen P; Kristiansen C; Stelmach M; Santoni-Rugiu E; Ulhøi MP; Dydensborg AB; Dünweber C; Andersen JL
Acta Oncol; 2023 Dec; 62(12):1775-1783. PubMed ID: 37815923
[TBL] [Abstract] [Full Text] [Related]
5. clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Baba T; Kusumoto M; Kato T; Kurihara Y; Sasaki S; Oikado K; Saito Y; Endo M; Fujiwara Y; Kenmotsu H; Sata M; Takano T; Kato K; Hirata K; Katagiri T; Saito H; Kuwano K
Int J Clin Oncol; 2023 Dec; 28(12):1585-1596. PubMed ID: 37787866
[TBL] [Abstract] [Full Text] [Related]
6. Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.
Grambozov B; Kalantari F; Beheshti M; Stana M; Karner J; Ruznic E; Zellinger B; Sedlmayer F; Rinnerthaler G; Zehentmayr F
Radiother Oncol; 2023 Aug; 185():109728. PubMed ID: 37301259
[TBL] [Abstract] [Full Text] [Related]
7. Comparison of outcome after stereotactic ablative radiotherapy of patients with metachronous lung versus primary lung cancer.
Benzaquen J; Bondiau PY; Otto J; Marquette CH; Berthet JP; Naghavi AO; Schiappa R; Hannoun-Levi JM; Padovani B; Doyen J
Radiat Oncol; 2023 Jun; 18(1):97. PubMed ID: 37287020
[TBL] [Abstract] [Full Text] [Related]
8. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
Abbosh C; Frankell AM; Harrison T; Kisistok J; Garnett A; Johnson L; Veeriah S; Moreau M; Chesh A; Chaunzwa TL; Weiss J; Schroeder MR; Ward S; Grigoriadis K; Shahpurwalla A; Litchfield K; Puttick C; Biswas D; Karasaki T; Black JRM; Martínez-Ruiz C; Bakir MA; Pich O; Watkins TBK; Lim EL; Huebner A; Moore DA; Godin-Heymann N; L'Hernault A; Bye H; Odell A; Roberts P; Gomes F; Patel AJ; Manzano E; Hiley CT; Carey N; Riley J; Cook DE; Hodgson D; Stetson D; Barrett JC; Kortlever RM; Evan GI; Hackshaw A; Daber RD; Shaw JA; Aerts HJWL; Licon A; Stahl J; Jamal-Hanjani M; ; Birkbak NJ; McGranahan N; Swanton C
Nature; 2023 Apr; 616(7957):553-562. PubMed ID: 37055640
[TBL] [Abstract] [Full Text] [Related]
9. One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy.
Hager T; Borchert S; Wessolly M; Mathilakathu A; Mairinger E; Kollmeier J; Mairinger T; Hegedus B; Greimelmaier K; Wohlschlaeger J; Herrmann K; Mairinger FD
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047331
[TBL] [Abstract] [Full Text] [Related]
10. Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China.
Ma Y; Shi H; Zhao G; Liu X; Cai J; Li G; Chen W; Lei Y; Ye L; Fu C; Zhao L; Zhou Y; Huang Y
Front Immunol; 2023; 14():1012166. PubMed ID: 36926333
[TBL] [Abstract] [Full Text] [Related]
11. Genomic Characteristics and the Potential clinical Implications in Oligometastatic Non-Small Cell lung cancer.
Liao R; Chen K; Li J; He H; Yi G; Huang M; Chen R; Shen L; Zhang X; Xu Z; Yang Z; Peng Y
Cancer Res Treat; 2023 Jul; 55(3):814-831. PubMed ID: 36634615
[TBL] [Abstract] [Full Text] [Related]
12. Evaluate the Prognosis of
Cao J; J Gu J; Liang Y; Wang B
Technol Cancer Res Treat; 2022; 21():15330338221138213. PubMed ID: 36524293
[No Abstract] [Full Text] [Related]
13. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.
Li D; Jiang H; Jin F; Pan L; Xie Y; Zhang L; Li C
Genes Genomics; 2023 Jan; 45(1):93-102. PubMed ID: 36445572
[TBL] [Abstract] [Full Text] [Related]
14. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract] [Full Text] [Related]
15. Novel evidence for the prognostic impact of β-blockers in solid cancer patients receiving immune checkpoint inhibitors.
Yan X; Liu P; Li D; Hu R; Tao M; Zhu S; Wu W; Yang M; Qu X
Int Immunopharmacol; 2022 Dec; 113(Pt A):109383. PubMed ID: 36330916
[TBL] [Abstract] [Full Text] [Related]
16. Nivolumab-induced radiation recall pneumonitis in non-small-cell lung cancer patients with thoracic radiation therapy.
Noda-Narita S; Naito T; Udagawa H; Goto K; Miyawaki T; Mamesaya N; Nakashima K; Kenmotsu H; Shimokawaji T; Kato T; Hakozaki T; Okuma Y; Nakamura M; Nakayama Y; Watanabe H; Kusumoto M; Ohe Y; Horinouchi H
Cancer Sci; 2023 Feb; 114(2):630-639. PubMed ID: 36285515
[TBL] [Abstract] [Full Text] [Related]
17. [Expression and prognostic value of programmed cell death ligand 1 in patients with locally advanced and non-EGFR-mutated non-small cell lung cancer receiving concurrent chemoradiotherapy].
Xue WJ; Bi N; Yang L; Wang X; Dong JY; Zhang T; Wu LF; Wang LH
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):406-411. PubMed ID: 35144339
[No Abstract] [Full Text] [Related]
18. Relationship between Nutritional Status and clinical outcome in Patients Treated for lung cancer.
Polański J; Chabowski M; Świątoniowska-Lonc N; Dudek K; Jankowska-Polańska B; Zabierowski J; Mazur G
Nutrients; 2021 Sep; 13(10):. PubMed ID: 34684333
[TBL] [Abstract] [Full Text] [Related]
19. Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
Unterrainer M; Taugner J; Käsmann L; Tufman A; Reinmuth N; Li M; Mittlmeier LM; Bartenstein P; Kunz WG; Ricke J; Belka C; Eze C; Manapov F
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1407-1416. PubMed ID: 34664091
[TBL] [Abstract] [Full Text] [Related]
20. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell lung cancer.
Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
[TBL] [Abstract] [Full Text] [Related]
[Next]
